Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

NGS-based molecular karyotyping of multiple myeloma: results from the GEM12 clinical trial

  • Rosa-Rosa, Juan Manuel
  • Cuenca, Isabel
  • Medina, Alejandro
  • Vázquez Urio, Iria
  • Sánchez de la Cruz, Andrea
  • Buenache, Natalia
  • Sánchez Pérez, Ricardo
  • Jiménez, Cristina
  • Rosiñol, Laura
  • Gutiérrez, Norma C.
  • Ruiz-Heredia, Yanira
  • Barrio Santiago
  • Oriol, Albert
  • Martín-Ramos, María-Luisa
  • Blanchard, María-Jesús
  • Ayala, Rosa
  • Ríos-Tamayo, Rafael
  • Sureda, Anna
  • Hernández, Miguel-Teodoro
  • Rubia, Javier de la
  • Alkorta Aranburu, Gorka
  • Agirre, Xabier
  • Bladé, Joan
  • Mateos, María-Victoria
  • Lahuerta, Juan-José
  • San-Miguel, Jesús F.
  • Calasanz, María José
  • García-Sanz, Ramón
  • Martínez-López, Joaquín
Next-generation sequencing (NGS) has greatly improved our ability to detect the genomic aberrations occurring in multiple myeloma (MM); however, its transfer to routine clinical labs and its validation in clinical trials remains to be established. We designed a capture-based NGS targeted panel to identify, in a single assay, known genetic alterations for the prognostic stratification of MM. The NGS panel was designed for the simultaneous study of single nucleotide and copy number variations, insertions and deletions, chromosomal translocations and V(D)J rearrangements. The panel was validated using a cohort of 149 MM patients enrolled in the GEM2012MENOS65 clinical trial. The results showed great global accuracy, with positive and negative predictive values close to 90% when compared with available data from fluorescence in situ hybridization and whole-exome sequencing. While the treatments used in the clinical trial showed high efficacy, patients defined as high-risk by the panel had shorter progression-free survival (p = 0.0015). As expected, the mutational status of TP53 was significant in predicting patient outcomes (p = 0.021). The NGS panel also efficiently detected clonal IGH rearrangements in 81% of patients. In conclusion, molecular karyotyping using a targeted NGS panel can identify relevant prognostic chromosomal abnormalities and translocations for the clinical management of MM patients., The study was supported by the Accelerator Grant: next steps: Early detection and intervention: Understanding the mechanisms of transformation and hidden resistance of incurable hematological malignancies, grants from Instituto de Salud Carlos III PI15/01484 and CRIS Foundation 2020/0063 and 2021/0088.